Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Minority Interest (2016 - 2018)

Coherus Oncology's Minority Interest history spans 5 years, with the latest figure at -$1.3 million for Q2 2018.

  • For Q2 2018, Minority Interest fell 4.52% year-over-year to -$1.3 million; the TTM value through Jun 2018 reached -$1.3 million, down 4.52%, while the annual FY2017 figure was -$1.3 million, 9.89% down from the prior year.
  • Minority Interest for Q2 2018 was -$1.3 million at Coherus Oncology, down from -$1.3 million in the prior quarter.
  • Across five years, Minority Interest topped out at -$44000.0 in Q4 2014 and bottomed at -$1.3 million in Q2 2018.
  • The 5-year median for Minority Interest is -$1.1 million (2016), against an average of -$872250.0.
  • The largest annual shift saw Minority Interest tumbled 1540.91% in 2015 before it fell 4.52% in 2018.
  • A 5-year view of Minority Interest shows it stood at -$44000.0 in 2014, then tumbled by 1540.91% to -$722000.0 in 2015, then tumbled by 62.47% to -$1.2 million in 2016, then dropped by 9.89% to -$1.3 million in 2017, then decreased by 4.03% to -$1.3 million in 2018.
  • Per Business Quant, the three most recent readings for CHRS's Minority Interest are -$1.3 million (Q2 2018), -$1.3 million (Q1 2018), and -$1.3 million (Q4 2017).